Alirocumab 150 MG/ML subcutaneous injection
ASAP-SVG, QR#32711/1
Approved small_molecule terminated
Quick answer
Alirocumab 150 MG/ML subcutaneous injection for Saphenous Vein Graft Atherosclerosis is a Approved program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Saphenous Vein Graft Atherosclerosis
- Phase
- Approved
- Modality
- small_molecule
- Status
- terminated